Shanghai Junshi Biosciences Co.Ltd(688180) : vv116 early treatment of mild to moderate covid-19 pneumonia phase III registered clinical study reached the primary endpoint

Shanghai Junshi Biosciences Co.Ltd(688180) ( Shanghai Junshi Biosciences Co.Ltd(688180) ) announcement on May 23, The product of oral nucleoside anti SARS cov-2 drug vv116 tablets (project code: jt001/vv116, referred to as “vv116”) jointly developed by the company’s holding subsidiary juntuo biology and Wangshan wangshui has reached the primary end point preset in the phase III registered clinical study (nct05341609) on the early treatment of binematavir tablets / ritonavir tablets (paxlovid) for mild to moderate novel coronavirus pneumonia (“covid-19”). The company will communicate with the regulatory authorities on the submission of new drug listing applications in the near future.